Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside

TIPRANKS04-02

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Rein Therapeutics today and set a price target of $10.00. Brandon Folkes has give...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624166500?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624166500","market":"fut","top_or_hot":-1,"title":"Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside","media":"TIPRANKS","content":"<div>\n<p>H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Rein Therapeutics today and set a price target of $10.00. Brandon Folkes has give...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/rein-therapeutics-regulatory-overhang-removed-and-phase-2-ipf-progress-underscore-best‑in‑class-potential-and-undervalued-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRein Therapeutics: Regulatory Overhang Removed and Phase 2 IPF Progress Underscore Best‑in‑Class Potential and Undervalued Upside\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/ratings/rein-therapeutics-regulatory-overhang-removed-and-phase-2-ipf-progress-underscore-best‑in‑class-potential-and-undervalued-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Rein Therapeutics today and set a price target of $10.00. Brandon Folkes has give...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/rein-therapeutics-regulatory-overhang-removed-and-phase-2-ipf-progress-underscore-best‑in‑class-potential-and-undervalued-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.tipranks.com/news/ratings/rein-therapeutics-regulatory-overhang-removed-and-phase-2-ipf-progress-underscore-best‑in‑class-potential-and-undervalued-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","article_id":"2624166500","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/rein-therapeutics-regulatory-overhang-removed-and-phase-2-ipf-progress-underscore-best‑in‑class-potential-and-undervalued-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624166500","pubTimestamp":1775141725,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Rein Therapeutics today and set a price target of $10.00. Brandon Folkes has give...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股","BK4097":"系统软件","BK4139":"生物科技","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","PRGS":"Progress Software Corporation"},"translate_title":"Rein Therapeutics：监管悬而未决的问题已消除，IPF 2期进展凸显了同类最佳的潜力和被低估的上行空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"PRGS":1.5},"content_text":"H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Rein Therapeutics today and set a price target of $10.00. Brandon Folkes has give...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624166500","isCrawlerRequest":true}